Blog
RSS FeedPosted by Michael Wonder on 25 Apr 2021
Public Summary Documents (rejections/deferrals/other matters) - December 2020 PBAC intracycle meeting
23 April 2021 - The Public Summary Documents (rejections/deferrals/other matters) from the December 2020 PBAC intracycle meeting are now available. ...
Posted by Michael Wonder on 22 Apr 2021
TGA publishes AusPAR for Zolgensma
22 April 2021 - Rapid publication following approval. ...
Posted by Michael Wonder on 16 Apr 2021
ICER publishes final evidence report and policy recommendations on therapies for lupus nephritis
16 April 2021 - For belimumab and voclosporin, independent appraisal committee votes highlight the importance of several potential benefits of both ...
Posted by Michael Wonder on 09 Apr 2021
PBAC Public Summary Documents - December 2020 intracycle meeting
9 April 2021 - The Public Summary Documents (positive recommendations) from the December 2020 PBAC intracycle meeting are now available. ...
Posted by Michael Wonder on 22 Mar 2021
PBAC publishes sham Public Summary Document for upadacitinib
22 March 2021 - The outcome section makes absolutely no reference to the issue at hand. ...
Posted by Michael Wonder on 20 Mar 2021
PBAC Public Summary Documents (first time rejections and deferrals) - November 2020 meeting
19 March 2021 - The Public Summary Documents (first time rejections and deferrals) from the November 2020 PBAC meeting are now ...
Posted by Michael Wonder on 10 Mar 2021
PBAC updates Public Summary Document for medicine without a published outcome
11 March 2021 - The Department of Health has updated the Public Summary Document for adalimumab (Humira) from the July ...
Posted by Michael Wonder on 05 Mar 2021
PBAC Public Summary Documents - November 2020 meeting
5 March 2021 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2020 PBAC ...
Posted by Michael Wonder on 15 Feb 2021
Post-market review of medicines for smoking cessation – stakeholder forum outcome
15 February 2021 - A stakeholder forum was held for the post-market review of medicines for smoking cessation via webinar on ...
Posted by Michael Wonder on 28 Jan 2021
ICER publishes evidence report on roxadustat for treating anaemia in chronic kidney disease
28 January 2021 - Other than a proven ability to reduce the need for intravenous iron supplements, the evidence is insufficient ...
Posted by Michael Wonder on 22 Jan 2021
ICER publishes evidence report on therapies for high cholesterol
22 January 2021 - The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a ...
Posted by Michael Wonder on 22 Jan 2021
ICER releases draft evidence report on therapies for lupus nephritis
22 January 2021 - Public comment period now open until 18 February 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 16 Jan 2021
PBAC Public Summary Documents (rejections/deferrals/other matters) - September 2020 intracycle meeting
15 January 2021 - The Public Summary Documents (rejections/deferrals/other matters) from the September 2020 PBAC untracycle meeting are now available. ...
Posted by Michael Wonder on 21 Dec 2020
Closure of the post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis
21 December 2020 - A plain language summary for the post-market review of the use of biologics in the treatment ...
Posted by Michael Wonder on 18 Dec 2020
Report on the collection of under co-payment data 2019-20
18 December 2020 - The report on the collection of under co-payment data 2019-20 is now available. ...